Assetmark, Inc Genmab A/S Transaction History

Assetmark, Inc

$45.6 Billion
Q3 2025

A detailed history of Assetmark, Inc transactions in Genmab A/S stock. As of the latest transaction made, Assetmark, Inc holds 9,266 shares of GMAB stock, worth $267,231. This represents 0.0% of its overall portfolio holdings.

Number of Shares

9,266

Previous 216 4189.81%

Holding current value

$267,231

Previous $4,000 7000.0%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 06, 2025	BUY	$20.3 - $30.67 $183,715 - $277,563	9,050 Added 4189.81%	9,266 $284,000
Q2 2025 Aug 04, 2025	SELL	$17.98 - $23.09 $35 - $46	-2 Reduced 0.92%	216 $4,000
Q1 2025 May 06, 2025	SELL	$18.69 - $24.14 $334,382 - $431,888	-17,891 Reduced 98.8%	218 $4,000
Q4 2024 Feb 06, 2025	SELL	$20.02 - $24.15 $1.29 Million - $1.56 Million	-64,520 Reduced 78.08%	18,109 $377,000
Q3 2024 Nov 01, 2024	BUY	$23.84 - $28.48 $274,612 - $328,061	11,519 Added 16.2%	82,629 $2.01 Million
Q2 2024 Aug 13, 2024	BUY	$25.13 - $30.27 $147,890 - $178,138	5,885 Added 9.02%	71,110 $1.79 Million
Q1 2024 May 06, 2024	BUY	$26.43 - $32.77 $573,716 - $711,338	21,707 Added 49.88%	65,225 $1.95 Million
Q4 2023 Feb 09, 2024	BUY	$27.94 - $35.44 $73,649 - $93,419	2,636 Added 6.45%	43,518 $1.39 Million
Q3 2023 Oct 27, 2023	BUY	$35.27 - $42.24 $141,820 - $169,847	4,021 Added 10.91%	40,882 $1.44 Million
Q2 2023 Aug 11, 2023	BUY	$37.4 - $42.94 $282,594 - $324,454	7,556 Added 25.78%	36,861 $1.4 Million
Q1 2023 May 05, 2023	BUY	$34.88 - $43.22 $150,611 - $186,623	4,318 Added 17.28%	29,305 $1.11 Million
Q4 2022 Feb 10, 2023	SELL	$33.8 - $47.06 $12,539 - $17,459	-371 Reduced 1.46%	24,987 $1.06 Million
Q3 2022 Nov 01, 2022	BUY	$31.52 - $373.61 $188,899 - $2.24 Million	5,993 Added 30.95%	25,358 $815,000
Q2 2022 Aug 03, 2022	BUY	$26.83 - $38.57 $179,519 - $258,071	6,691 Added 52.79%	19,365 $629,000
Q1 2022 May 13, 2022	BUY	$30.95 - $39.68 $129,773 - $166,378	4,193 Added 49.44%	12,674 $459,000
Q4 2021 Feb 14, 2022	SELL	$35.87 - $47.12 $1.42 Million - $1.86 Million	-39,573 Reduced 82.35%	8,481 $336,000
Q3 2021 Nov 12, 2021	BUY	$41.55 - $48.72 $176,753 - $207,254	4,254 Added 9.71%	48,054 $2.1 Million
Q2 2021 Aug 16, 2021	BUY	$32.88 - $44.57 $477,614 - $647,423	14,526 Added 49.62%	43,800 $1.79 Million
Q1 2021 May 14, 2021	BUY	$30.92 - $44.4 $75,011 - $107,714	2,426 Added 9.04%	29,274 $961,000
Q4 2020 Feb 10, 2021	BUY	$33.66 - $40.76 $282,239 - $341,772	8,385 Added 45.42%	26,848 $1.09 Million
Q3 2020 Nov 13, 2020	BUY	$33.07 - $38.68 $506,037 - $591,881	15,302 Added 484.09%	18,463 $676,000
Q2 2020 Aug 11, 2020	SELL	$20.05 - $33.89 $17,263 - $29,179	-861 Reduced 21.41%	3,161 $107,000
Q1 2020 May 12, 2020	SELL	$17.15 - $25.22 $21,934 - $32,256	-1,279 Reduced 24.13%	4,022 $85,000
Q4 2019 Feb 11, 2020	BUY	$18.88 - $24.14 $22,278 - $28,485	1,180 Added 28.63%	5,301 $118,000
Q3 2019 Nov 13, 2019	BUY	$18.0 - $21.38 $74,178 - $88,106	4,121 New	4,121 $83,000

Others Institutions Holding GMAB

# of Institutions

256

Shares Held

65.7M

Call Options Held

32.5K

Put Options Held

55K

View Full List

About GENMAB A/S

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $19B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

More about GMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Assetmark, Inc with notifications on news.

Account